Privately-held Italian drugmaker Alfasigma has signed an agreement with Belgium’s Galapagos (Euronext: GLPG) to acquire the latter’s Jyseleca (filgotinib) business.
The agreement follows the signing of a Letter of Intent as announced on October 30, 2023 and marks a significant milestone in Alfasigma’s ongoing growth strategy.
Alfasigma will acquire the entire Jyseleca business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca and around 400 Galapagos positions in 14 European countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze